127 related articles for article (PubMed ID: 25862856)
1. Gene expression analysis for evaluation of potential biomarkers in hepatocellular carcinoma.
Hass HG; Jobst J; Scheurlen M; Vogel U; Nehls O
Anticancer Res; 2015 Apr; 35(4):2021-8. PubMed ID: 25862856
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma.
Jia HL; Ye QH; Qin LX; Budhu A; Forgues M; Chen Y; Liu YK; Sun HC; Wang L; Lu HZ; Shen F; Tang ZY; Wang XW
Clin Cancer Res; 2007 Feb; 13(4):1133-9. PubMed ID: 17317821
[TBL] [Abstract][Full Text] [Related]
3. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
[TBL] [Abstract][Full Text] [Related]
4. Detection of α-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR.
Yan D; He Q; Chen Y; Wang L; Zhang X
J Clin Lab Anal; 2011; 25(2):113-7. PubMed ID: 21438004
[TBL] [Abstract][Full Text] [Related]
5. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin.
Yu MC; Lee YS; Lin SE; Wu HY; Chen TC; Lee WC; Chen MF; Tsai CN
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S455-63. PubMed ID: 21822558
[TBL] [Abstract][Full Text] [Related]
6. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
[TBL] [Abstract][Full Text] [Related]
7. Correlation between HBV protein preS2 and tumor markers of hepatocellular carcinoma.
Luan F; Liu B; Zhang J; Cheng S; Zhang B; Wang Y
Pathol Res Pract; 2017 Sep; 213(9):1037-1042. PubMed ID: 28869105
[TBL] [Abstract][Full Text] [Related]
8. Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers.
Liu X; Wang SK; Zhang K; Zhang H; Pan Q; Liu Z; Pan H; Xue L; Yen Y; Chu PG
Carcinogenesis; 2015 Feb; 36(2):232-42. PubMed ID: 25542894
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expressions of annexin A10 short isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma.
Peng SY; Ou YH; Chen WJ; Li HY; Liu SH; Pan HW; Lai PL; Jeng YM; Chen DC; Hsu HC
Int J Oncol; 2005 Apr; 26(4):1053-61. PubMed ID: 15754002
[TBL] [Abstract][Full Text] [Related]
10. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
Llovet JM; Chen Y; Wurmbach E; Roayaie S; Fiel MI; Schwartz M; Thung SN; Khitrov G; Zhang W; Villanueva A; Battiston C; Mazzaferro V; Bruix J; Waxman S; Friedman SL
Gastroenterology; 2006 Dec; 131(6):1758-67. PubMed ID: 17087938
[TBL] [Abstract][Full Text] [Related]
11. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
Fu SJ; Qi CY; Xiao WK; Li SQ; Peng BG; Liang LJ
Surgery; 2013 Sep; 154(3):536-44. PubMed ID: 23601901
[TBL] [Abstract][Full Text] [Related]
12. Molecular background of alpha-fetoprotein in liver cancer cells as revealed by global RNA expression analysis.
Saito S; Ojima H; Ichikawa H; Hirohashi S; Kondo T
Cancer Sci; 2008 Dec; 99(12):2402-9. PubMed ID: 19038010
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Osteopontin as a Biomarker in Hepatocellular Carcinomas in Egyptian Patients with Chronic HCV Cirrhosis.
Abdel-Hafiz SM; Hamdy HE; Khorshed FM; Aboushousha TS; Safwat G; Saber MA; Seleem M; Soliman AH
Asian Pac J Cancer Prev; 2018 Apr; 19(4):1021-1027. PubMed ID: 29693976
[TBL] [Abstract][Full Text] [Related]
14. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma.
Kim J; Ki SS; Lee SD; Han CJ; Kim YC; Park SH; Cho SY; Hong YJ; Park HY; Lee M; Jung HH; Lee KH; Jeong SH
Am J Gastroenterol; 2006 Sep; 101(9):2051-9. PubMed ID: 16848813
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellualar carcinoma serum markers.
Bertino G; Ardiri A; Malaguarnera M; Malaguarnera G; Bertino N; Calvagno GS
Semin Oncol; 2012 Aug; 39(4):410-33. PubMed ID: 22846859
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of tumor-associated trypsin inhibitor (SPINK1/TATI) in hepatitis C-associated hepatocellular carcinoma: potential implications for viral hepatocarcinogenesis.
Hass HG; Jobst J; Vogel U; Scheurlen M; Nehls O
Oncol Res Treat; 2014; 37(12):732-8. PubMed ID: 25531719
[TBL] [Abstract][Full Text] [Related]
18. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors].
Li J; Wei L
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.
Pan HW; Ou YH; Peng SY; Liu SH; Lai PL; Lee PH; Sheu JC; Chen CL; Hsu HC
Cancer; 2003 Jul; 98(1):119-27. PubMed ID: 12833464
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]